Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study

Bibliographic Details
Main Authors: Garcia-Manero, G, Daver, NG, Xu, J, Chao, M, Chung, T, Tan, A, Wang, V, Wei, A, Vyas, P, Sallman, DA
Format: Conference item
Language:English
Published: American Society of Clinical Oncology 2021

Similar Items